Epigenetic inactivation of RASSF10 through promoter hypermethylation has been reported in various tumor entities including lung cancer, thyroid cancer, melanoma and several others [17,18,19,20,21,22]. Here, RASSF10 is linked to thyroid gland carcinoma.